V ascular trauma, induced by burn or by mechanical disruption, such as during surgical procedures, leads to a cascade of events that result in the chemoattraction of inflammatory cells and other cell types to the site of injury. 1 Production and release of proangiogenic factors such as VEGF and basic fibroblast growth factor 2 (FGF-2) may potentiate the recruitment of inflammatory cells including monocytes, 2 as well as other nonhematopoietic cell types such as circulating endothelial precursor cells (CEPs), 3, 4 to the site of injured vascular tissue, accelerating vascular healing.
Vascular healing is a complex process and may require rapid endothelialization to prevent fatal complications such as thrombosis or bleeding. Two possible sources of endothelialization are (1) migration and co-option of preexisting vascular wall endothelial cells (ECs) or (2) recruitment of CEPs from the stem-cell reservoirs such as bone marrow (BM). CEPs may reflect the phenotype of embryonic angioblasts, which are migratory ECs with the capacity to circulate, proliferate, and differentiate into mature ECs but have neither acquired characteristic markers of mature ECs nor formed lumina.
We have shown that allogeneic sex-mismatched BM transplantation resulted in the transfer of CEPs to recipient dogs. 5 In humans, evidence for CEPs originates from patients implanted with a left ventricular assist device (LVAD), where the surface of the titanium housing of LVADs is colonized with BM-derived circulating CD34 ϩ EC-like cells. 6 However, because BM contains both mature ECs as well as BM-derived CEPs, these studies did not conclusively demonstrate the existence of a phenotypically and functionally distinct population of CEPs. Moreover, discrimination between CEPs and mature ECs or hematopoietic cells is complicated by the fact that subsets of hematopoietic cells express markers similar to those of ECs.
In search of a BM-derived, CEP-specific marker, we have found that AC133, a novel hematopoietic stem-cell marker, is also expressed on subsets of CD34 ϩ cells. 7 AC133 ϩ CEPs express vascular endothelial growth factor receptor 2 (VEGFR2) and are dependent on VEGF for survival and in vitro expansion. AC133 ϩ VEGFR2 ϩ CEPs isolated from cord blood, BM, or fetal liver proliferate in vitro in an anchorageindependent manner and can be induced to undergo migration or differentiate into mature adherent AC133 Ϫ mature ECs. 7 Several studies have capitalized on the in vitro growth capacity and differentiation profile of CEPs to distinguish between mature fallout vessel-derived endothelium and BMderived CEPs. Using fluorescent in situ hybridization analysis to detect the Y chromosome in blood samples from BM transplant recipients who received gender-mismatched stem cells, Lin et al 8 could distinguish between vessel wall and BM-derived endothelial cells. They show that in vitroderived ECs form adherent colonies during early phases of culture (9 days after plating) and undergo 6-fold expansion and are derived predominantly from the recipient vessel wall, whereas ECs derived from late-outgrowth endothelial colonies (CFU-ECs, 30 days after culture) undergo 98-fold expansion and mostly generate from transplanted donor BM cells. In this regard, the potential of forming late-outgrowth colonies and expression of AC133 provide for surrogate markers to identify and quantify the numbers of human BM-derived CEPs.
Because rapid endothelialization of denuded injured vessels is essential to avoid fatal complications, we hypothesized that elevation of plasma VEGF levels immediately after vascular trauma may promote CEP mobilization into the peripheral circulation. In the present study, we demonstrate that in burn patients and those who undergo coronary artery bypass grafting (CABG), there is a rapid elevation of VEGF levels followed by immediate mobilization, within 6 to 12 hours of vascular trauma, of VEGFR2 ϩ AC133 ϩ cells into the peripheral circulation. Given that a significant number of VEGFR2 ϩ cells have the capacity to form late-outgrowth colonies and also express the stem-cell marker AC133, they can be considered as BM-derived CEPs. These data suggest that CEPs may act as first-aid angiogenic modules rapidly mobilized to enhance the endothelialization of denuded prothrombotic injured vasculature. Isolation and ex vivo expansion of these cells may facilitate the development of strategies to augment and accelerate vascular healing in patients with profound vascular insufficiencies.
Materials and Methods

Collection of Peripheral Blood Samples and Isolation of Mononuclear Cells
Permission to perform these studies was approved by the investigational review board at Cornell University Medical College. Samples were taken from patients who had Ͼ15% burn injury (nϭ8). Peripheral blood (4 to 5 mL) was taken at 12, 24, 48, and 72 hours and on the 7th and 14th days. Blood (4 to 5 mL) was also taken from patients (nϭ7) who underwent CABG. Samples were taken preoperatively at 6, 12, 24, 48, and 72 hours and on the 4th day.
The blood samples from burn and CABG patients were collected in heparinized tubes. Blood (5 mL) was diluted with HBSS (Life Technologies) and overlaid on top of a Ficoll preparation (Accue Prep Lymphocytes, Accurate Chemical & Scientific Corp). The buffy coat, containing the peripheral blood mononuclear cells (PBMNCs), was isolated and washed twice in HBSS at 1800g for 10 minutes. Finally, the PBMNCs were resuspended in serum-free medium (X-vivo 20, BioWhittaker). These cells were studied for the expression of endothelial-specific markers and formation of lateoutgrowth endothelial colonies.
Flow Cytometry Studies
PBMNCs, cultured in serum-free medium X-vivo 20, were incubated with 1.5 L FITC (green fluorescence) labeled high-affinity nonneutralizing monoclonal antibody (MoAb) to VEGFR2 (clone 6.64, Imclone Systems Inc) and 1.5 L phycoerythrin (PE; red fluorescence) labeled anti-CD15 antibody (Sigma), for 20 minutes at 4°C. Nonviable cells were excluded by propidium iodide (PI; 30 mol/L, Becton Dickinson). The number of positive cells was compared with IgG isotype control (FITC, PE; Immunotech) and quantified using a Coulter Elite flow cytometer (Coulter). Other endothelial markers studied were vascular endothelial cadherin (VE-cadherin) (BV9 clone, Imclone Systems Inc) and AC133 (Miltenyi Biotech). For analysis in burn patients, samples taken from normal age and gender-matched subjects were used as control, and preoperative samples were used as control in the CABG patients.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis of PBMNCs
Total RNA from PBMNCs of burn and CABG patients at different time points was obtained using Tri-Zol (Life Technologies), according to the manufacturer's instructions. The first-strand cDNA was synthesized using the T-Primed First Strand Kit (Amersham Pharmacia Biotech Inc), amplified by Taq DNA polymerase (Advantage cDNA Polymerase Mix, Clontech) in a 25-L reaction mixture, including 10 mmol/L dNTP (MBI Fermentas Inc) and 10 mol/L of each primer (Genelink). PCR was performed using a PCR thermal cycler (MWG Biotech). The PCR program used to amplify VEGFR2, VE-cadherin, and ␤-actin had the following parameters: 5 minutes initial denaturation at 94°C, annealing at 60°C for 1 minute, and 30 seconds of elongation at 72°C. This initial cycle was followed by 35 cycles of denaturation at 94°C for 45 seconds, annealing at 60°C for 45 seconds, and 2 minutes of elongation at 72°C, followed by 7 minutes of extension at 72°C. Subsequently, PCR products were visualized in 1.5% ethidium bromide-stained agarose gels. Human umbilical vein endothelial cell (HUVEC) cDNA was used as a positive control. RNA from normal donors for the burn patients and preoperative samples from the CABG patients were used as a control for baseline mRNA expression. 
Late-Outgrowth Endothelial Colony Assay
To evaluate the potential of mobilized PBMNCs as CEPs, we used a protocol developed by Lin et al, 8 with minor modifications. Freshly isolated PBMNCs, obtained 12 hours after trauma, were cultured in endothelial growth medium (M199, Gibco BRL) supplemented with 20% FBS (HyClone), endothelial cell growth factor (30 g/mL), FGF (5 ng/mL, human recombinant basic FGF [Sigma]), heparin (5 U/mL), penicillin (100 U/mL), streptomycin (100 g/mL), and fungizone (0.25 g/mL). These cells were placed on 12-well plates and coated with 0.2% gelatin. The plates were incubated at 37°C in a humidified environment with 5% CO 2 . This process resulted in attachment of cells consisting mostly of monocytes or mature endothelial colonies on the well plates. Nonadherent cells were transferred after 4 to 5 days to other wells coated with 0.2% gelatin and grown in endothelial growth medium. Each week, for up to 2 weeks, the nonadherent cells were transferred to fresh plates to assess for the formation of late-outgrowth colonies.
Endothelial colonies were identified by metabolic uptake of DiI-acetylated-LDL (DiI-Ac-LDL) by incubating the cells with 1 g/mL of human DiI-Ac-LDL (PerImmune Inc) at 37°C for 5 hours and visualizing by fluorescence microscopy. For von Willebrand factor (vWF) staining, cells were rinsed with HBSS and fixed immediately with 4% paraformaldehyde for 10 minutes. A primary mouse antibody against human vWF (Dako) was used at 1:250 dilution. Biotinylated rat anti-mouse IgG (Vector Laboratories Inc) was used at 1:200 dilution. Streptavidin linked to FITC (Jackson ImmunoResearch Laboratories Inc) was used at a dilution of 1:200. Cells were visualized by fluorescence microscopy. HUVECs were used as positive control for DiI-Ac-LDL uptake and vWF staining. Adherent colonies incorporating DiI-Ac-LDL and coexpressing vWF, representing early outgrowths, were quantified every week. DiI-Ac-LDL ϩ vWF ϩ colonies derived from passaged nonadherent cells, which formed between 6 to 8 weeks, were considered as late-outgrowth colonies (CFU-ECs). Samples from the healthy donors were used as control in the burn patients and preoperative samples were used as control in the CABG patients.
VEGF Plasma Determination
Quantitative determination of VEGF in the plasma of patients or AdVEGF 165 -injected mice was determined by a specific human or murine VEGF ELISA using the Quantikine VEGF-ELISA kit (R&D Systems Inc), according to the manufacturer's instructions. Peripheral blood plasma samples were obtained at different time points from the burn and CABG patients. Plasma samples from healthy donors were used to determine the baseline VEGF levels for the burn patients, whereas in CABG patients, this was determined by analyzing the preoperative plasma levels of the patients. Plasma of mice injected with AdNull was used as control. Both assays have a sensitivity limit of 7 pg/mL. Samples were analyzed in triplicate.
In Vivo Adenoviral Delivery of VEGF
Immunocompetent mice (on BALB/C background), aged 8 weeks (Ͼ20 g) and sex-matched, were purchased from the Jackson Laboratory (Bar Harber, Maine) and maintained in germ-free conditions. Mice (nϭ6) received AdVEGF 165 
Flow Cytometry Studies on Mouse PBMNCs
Cells were costained with 1.5 L of FITC-labeled high-affinity MoAb to VEGFR2 (clone DC101, Imclone Systems Inc) and 1 L of PE (red fluorescence) labeled anti-CD11b antibody (Pharmingen) for 20 minutes at 4°C. The number of positive cells was compared with IgG isotype control (FITC, PE; Pharmingen). PI (30 mol/L) was used to exclude the nonviable cells. The cells were analyzed by using the Coulter Elite flow cytometer.
Statistical Analysis
A standard Student's t test was used to determine statistical differences.
Results
VEGF Plasma Levels Increase After Vascular Trauma
VEGF plasma levels from both burn and CABG patients increased immediately after vascular trauma, which peaked between 6 to 12 hours after injury, and then decreased gradually over a 2-day period ( Figures 1A and 1B) . VEGF levels were lower after 3 to 4 days of injury. These results suggest that vascular trauma induces a rapid but transient increase in plasma VEGF levels after trauma.
Vascular Trauma Induces Mobilization of PBMNCs Expressing mRNA for VEGFR2 and VE-Cadherin
We investigated whether the rapid increase in VEGF levels correlated with an increase in the number of circulating VEGFR2 ϩ PBMNCs. Peripheral blood samples from burn and CABG patients demonstrated VEGFR2 and VE-cadherin expression at the mRNA level, as determined by RT-PCR (Figures 2A and 2B ). VEGFR2 and VE-cadherin mRNA were present in the PBMNCs between 6 and 12 hours and then gradually decreased over time. Control samples for burn and CABG patients had virtually undetectable mRNA levels for any of these markers.
Characterization of Mobilized CEPs
The RT-PCR analysis of PBMNCs from burn and CABG patients suggested that after vascular trauma, a population of cells expressing VEGFR2 and VE-cadherin may be rapidly mobilized into the peripheral circulation. These results were subsequently confirmed by analysis of surface expression using flow cytometry (FACS).
Given that monocytes express Fc receptors and may give rise to false-positive results, the PBMNCs were also costained with CD15 to exclude mobilized cells of myeloid-monocytic lineage. VEGF levels are rapidly increased in burn and CABG patients. Plasma VEGF levels in burn (A) and CABG (B) patients were determined by ELISA. There was a rapid elevation (6 to 12 hours) of VEGF levels after trauma, followed by a gradual decrease over time (nϭ5 for burn, nϭ4 for CABG). Results shown are meanϮSD for plasma VEGF levels, in both burn and CABG patient samples.
Confirming the RT-PCR results, FACS analysis of PBMNCs obtained from burn and CABG patients showed a rapid increase in circulating VEGFR2
ϩ cells after 6 to 12 hours (Figures 3 and  4) . These cells were negative for the myeloid marker CD15 (see Figures 3A and 3B for a typical FACS profile). Samples from burn patients showed an average of 20 655Ϯ4077 VEGFR2 ϩ
CD15
Ϫ cells (5.1Ϯ1.04% of the total PBMNCs) mobilized 12 hours after burn injury ( Figure 4A) Figure 4B ). In these patients, at 12 and 24 hours after surgery, there was a sustained elevation of VEGFR2 ϩ CD15 Ϫ cells with an average of 17 800Ϯ5823 (4.5Ϯ1.45% of the total PBMNCs) and 11 467Ϯ4097 (2.8Ϯ1% of the total PBMNCs) cells (Figure 4B ), respectively. The number of VEGFR2 ϩ
Ϫ cells gradually decreased over a 3-to 4-day period, in both groups of patients. The last peripheral blood sample from burn patients was taken 14 days after injury and had 664Ϯ257 (0.20Ϯ0.03% of the total PBMNCs) VEGFR2 ϩ
Ϫ cells ( Figure 4A) . Similarly, the last sample from CABG patients was taken on the fourth day after surgery and showed 1329Ϯ408 (0.3Ϯ0.06% of the total PBMNCs) VEGFR2 ϩ
Ϫ cells ( Figure 4B ). These results demonstrate the presence of a small, but distinct, population of VEGFR2 ϩ
Ϫ cells within the PBMNC population of vascular trauma patients, which rapidly gets mobilized within 6 to 
hours after injury and then decreases gradually over a period of days.
Phenotypic Analysis of the VEGFR2
؉
CD15
؊ Cells
The peripheral blood samples from burn and CABG patients were further analyzed for the presence of other hematopoietic and endothelial markers by flow cytometry. The 12-hour time point was chosen, because it consistently showed, in both groups of patients, the highest number of mobilized CEPs. Twelve hours after injury, in both burn and CABG patients, there was a maximum increase in cells expressing VEcadherin and AC133 (Table) , which accompanied the maximum increase in VEGFR2 expression. There was a mean increase of 15 987Ϯ4555 (5.1Ϯ1.04% of the total PBMNCs) and 15 544Ϯ3390 (4.5Ϯ1.45% of the total PBMNCs) VEcadherin ϩ cells at 12 hours, in burn and CABG patients, respectively (Table) . Similarly, the increase in AC133 ϩ cells in burn and CABG patients was 8769Ϯ2019 (2.2Ϯ0.5% of the total PBMNCs) and 8342Ϯ2109 (2.1Ϯ0.51% of the total PBMNCs), respectively (Table) . Furthermore, as shown for VEGFR2, expression of these markers in the PBMNC population gradually decreased over a 2-to 3-day period (data not shown). These results suggest that the cell population mobilized after vascular trauma consists of VEGFR2 ϩ cells expressing VE-cadherin and AC133.
BM-Derived CEPs Are Present in a Significant Number of Mobilized PBMNCs
Emerging data suggest that late-outgrowth endothelial cells differentiating from the nonadherent population of plated PBMNCs represent a population of BM-derived anchorageindependent BM-derived CEPs characterized by high proliferative potential.
To assess the number of mobilized PBMNCs with the capacity of generating late-outgrowth colonies, PBMNCs mobilized from burn and CABG patients 12 hours after trauma were grown in vitro in conditions defined to support the formation of late-outgrowth colonies. 8 Typical endothelial colonies, with cobblestone morphology, appeared after 7 to 10 days of culture ( Figures 5A and 5B ) and showed both the metabolic incorporation of DiI-Ac-LDL as well as vWF staining ( Figure 5C ). These were the early-outgrowth endothelial colonies, which are presumably derived form mature fallout circulating ECs. Few endothelial colonies formed between 10 and 14 days of culture (Figures 5A and 5B) and were positive for both DiI-Ac-LDL and vWF ( Figure 5C ). These were also scored as the early outgrowths. On day 15, the nonadherent population was passed for a third time. The colonies formed between 6 and 8 weeks ( Figures 5A and 5B ) from this passaged nonadherent population were referred to as the late-outgrowth endothelial colonies (CFU-ECs). These late-outgrowth colonies were quantified based on their capacity to metabolically incorporate DiI-Ac-LDL and stain positively with vWF ( Figure 5C ). PBMNCs derived from control samples were able to form the early outgrowths but not the late outgrowths. We and others 7, 9 have shown that purified populations of AC133 have the capacity to form late-outgrowth colonies with a plating efficiency of 5%. On the basis of these results, we estimated that close to 12% of the mobilized AC133 cells were capable of forming late CFU-ECs. Collectively, these data show that a small, but significant, number of the mobilized circulating endothelial cells from burn and CABG patients, 12 hours after trauma, were BM-derived CEPs. *Peripheral blood obtained from burn and CABG patients at 12 hours after trauma. Values shown represent the absolute number of cells in 1 mL of peripheral blood. Numbers in parentheses represent the corresponding percentages in the total PBMNCs in 1 mL of peripheral blood. Figures 6A and 6B ). CD11b/CD18 (Mac-1) is primarily expressed on the myeloid-monocytic cells. In AdVEGF 165 -inoculated mice, there was a maximum increase in VEGF plasma levels at 24 hours (Figure 7 ), which correlated with the number of rapidly mobilized VEGFR2 ϩ CD11b Ϫ cells. VEGF levels gradually decreased over the next 2 weeks (Figure 7 ). AdNull vector (no transgene), which was used as a control, did not induce significant mobilization of VEGFR2 ϩ CD11b Ϫ (1.9Ϯ0.28%) cells (Figures 6A and 6B ). Circulating VEGFR2 ϩ CD11b Ϫ cells were still abundant (2.1Ϯ0.28%) in the AdVEGF 165 -injected mice after 7 days compared with control (AdNull-treated) mice (0.6Ϯ0.14%) ( Figure 6B) . Doses above 1.5ϫ10 8 pfu were toxic and resulted in the demise of the treated mice (data not shown). There were no signs of toxicity in mice treated with AdNull vectors at doses of up to 10 9 pfu. These data suggest that elevation of VEGF plasma levels induce a rapid mobilization of VEGFR2
Elevation of VEGF Plasma Levels in Mice
PBMNCs (
ϩ CD11b Ϫ cells in mice within a similar time frame to that seen for the mobilization of VEGFR2 ϩ CD15 Ϫ cells in burn and CABG patients. Plasma VEGF levels remained low in AdNull-injected mice ( Figure  7 ). These results suggest that, similar to burn or CABG patients, an acute but transient increase in mouse plasma VEGF levels promotes a rapid mobilization of VEGFR2 ϩ CD11b Ϫ cells into the peripheral circulation.
Discussion
Postnatal neovascularization is the process of new blood vessel formation from preexisting endothelial cells. 10 However, the origin of endothelial cells incorporated into the newly formed blood vessels has been the subject of intensive scrutiny. Emerging data have suggested that a subpopulation of BM-derived CEPs may contribute to new blood vessel formation. 5, [11] [12] [13] It has been shown that CEPs have the capacity of being recruited into ischemic tissues or growing tumors. 4, [13] [14] [15] In the present study, we have extended these observations by demonstrating that vascular trauma induces a very rapid but transient mobilization of a significant number of BM-derived VEGFR2 ϩ AC133 ϩ cells. Given the rapid entry of the CEPs into the peripheral circulation, it has been suggested that the chemocytokines released as a result of the vascular injury may induce mobilization of CEPs. Among the known chemocytokines, VEGF has been shown to be effective in mobilizing CEPs into the peripheral circulation. 3 Indeed, patients undergoing CABG or those who have suffered extensive burns, have elevated VEGF plasma levels, peaking 6 to 12 hours after vascular insult and gradually decreasing to baseline after 3 to 4 days. Elevated VEGF levels have also been measured in burn patients in a previous study. 16 However, it remained unclear whether this increase in circulating VEGF levels had any physiological significance. In this report, we demonstrate that a rise in circulating VEGF levels is accompanied by an increase in PBMNCs comprised of a significant number of BM-derived CEPs. There was a 50-fold increase, compared with preoperative level, in the number of circulating cells 6 to 12 hours after surgery in CABG patients, and a similar result was seen in those patients suffering from extensive burns. Similarly, we demonstrate that acute elevation of plasma VEGF in vivo in mice leads to increased circulation of VEGFR2 ϩ cells. Mice inoculated with adenoviral vectors encoding the VEGF 165 transgene showed a rapid but transient increase in circulating VEGFR2 ϩ CD11b Ϫ PBMNCs. These data suggest that, similar to the murine VEGF-induced mobilization of CEPs, acute elevation of VEGF levels in vascular trauma patients may be the primary factor inducing mobilization of CEPs. However, because vascular trauma also promotes the release of numerous known or as-yet unrecognized chemocytokines, other factors in addition to VEGF may also contribute to the mobilization of CEPs. Adherent proliferating colonies that formed in the first 2 weeks and late colonies that formed in the passaged cells during 6 to 8 weeks of initial culture were quantified for the metabolic incorporation of DiI-Ac-LDL (red) as well as vWF (green) staining (C). DiI-Ac-LDL ϩ vWF ϩ -adherent colonies that formed from passaged nonadherent cells, between 6 to 8 weeks of initial culture, were scored as late-outgrowth colonies (CFU-ECs), whereas those that formed from initial plating, within the first 3 weeks, were considered as early outgrowth colonies.
Vascular trauma may also result in the nonspecific introduction of mature vascular wall-derived ECs into the circulation. We have used the expression pattern of AC133 and the potential of late-outgrowth CFU-EC colony formation to estimate the number of BM-derived CEPs. We demonstrate that, on average, close to 40% of the mobilized VEGFR2 ϩ cells express AC133. In addition, we estimated that close to 12% of mobilized AC133 ϩ cells form late-outgrowth CFUECs. Collectively, these data suggest that a small, but significant, number of the mobilized PBMNCs are BMderived CEPs. It is intriguing that only the mobilized PBMNCs from earlier phases after the trauma were AC133 ϩ or formed late-outgrowth colonies, suggesting that the rapid increase in circulating BM-derived CEPs is the result of a chemokinetic process, rather than differentiation or maturation of a population of stem cells. Furthermore, the rapid increase in PBMNCs with endothelial precursor potential suggests that the number of CEPs in the adult BM may be greater than expected. Taken together, these results suggest that the rapid mobilization of CEPs, in response to a rise in circulating VEGF levels after trauma, may contribute to the revascularization of the injured tissues.
Strategies to enhance mobilization and incorporation of CEPs into impaired vascular beds may have important therapeutic implications. However, it remains to be demonstrated to what extent these mobilized CEPs contribute to the compromised vascular tissue and whether acceleration of their mobilization and homing may promote the vascular healing process. Nevertheless, as shown in the present study, therapies aimed at blocking mobilization of CEPs and other BM-derived cells into the peripheral circulation and subsequently into neovascularized tissues may have undesirable clinical complications. Finally, VEGF-induced mobilization of VEGFR2 ϩ
AC133
ϩ cells may facilitate the isolation of an enriched population of CEPs from the peripheral circulation, which may ultimately be used for gene therapy or ex vivo expansion. There was a rapid elevation (24 hours) of VEGF levels after AdVEGF 165 injection, followed by a gradual decrease over time (nϭ3). Results are the meanϮSD for plasma VEGF levels.
